{"id":13972,"date":"2013-12-13T15:32:32","date_gmt":"2013-12-13T14:32:32","guid":{"rendered":"http:\/\/www.invarena.cz\/?p=13972"},"modified":"2013-12-13T15:52:49","modified_gmt":"2013-12-13T14:52:49","slug":"studie-preziti-pacientu-s-rakovinou-se-vyrazne-prodlouzilo","status":"publish","type":"post","link":"https:\/\/www.invarena.cz\/?p=13972","title":{"rendered":"Studie: P\u0159e\u017eit\u00ed pacient\u016f s rakovinou se v\u00fdrazn\u011b prodlou\u017eilo"},"content":{"rendered":"

P\u0159e\u017eit\u00ed pacient\u016f s rakovinou v \u010cR se podle studie Eurocare5 v\u00fdrazn\u011b prodlou\u017eilo, v\u00fdjimkou je rakovina kone\u010dn\u00edku, kde je kv\u016fli mal\u00e9mu z\u00e1jmu lid\u00ed o screening pozdn\u00ed z\u00e1chyt.\u00a0Jinak je \u010cesko v lep\u0161\u00edm pr\u016fm\u011bru Evropy.<\/strong><\/p>\n

 <\/p>\n

Studie srovn\u00e1vala p\u011btilet\u00e9 p\u0159e\u017eit\u00ed v\u00edce ne\u017e deseti milion\u016f pacient\u016f z 29 evropsk\u00fdch zem\u00ed, diagnostikovan\u00fdch v letech 2000 a\u017e 2007. \u010cR dos\u00e1hla a\u017e o 15 procent lep\u0161\u00edch v\u00fdsledk\u016f ne\u017e zem\u011b v\u00fdchodn\u00ed Evropy, kam ji studie zem\u011bpisn\u011b \u0159ad\u00ed. V \u010cesku je p\u0159es 430.000 lid\u00ed, kte\u0159\u00ed se s rakovinou l\u00e9\u010d\u00ed nebo l\u00e9\u010dili.<\/p>\n

„U drtiv\u00e9 v\u011bt\u0161iny n\u00e1dor\u016f jsme z\u00e1sadn\u011b posko\u010dili v dosahovan\u00e9m p\u0159e\u017eit\u00ed, co\u017e n\u00e1s fakticky vy\u0159adilo z v\u00fdchodoevropsk\u00fdch zem\u00ed. Jsme v lep\u0161\u00edm pr\u016fm\u011bru Evropy, anebo na n\u011bj ztr\u00e1c\u00edme jen jednotkov\u00e9 body,“ \u0159ekl \u010cTK \u0159editel brn\u011bnsk\u00e9ho Institutu biostatiky a anal\u00fdz Ladislav Du\u0161ek, kter\u00fd \u010desk\u00e1 data pro celoevropskou studii kontroloval.<\/p>\n

Data evropsk\u00e9 studie zpracoval mezin\u00e1rodn\u00ed t\u00fdm pod veden\u00edm profesora Riccarda Capoccacia. Podle n\u011bj dobr\u00e1 zpr\u00e1va je, \u017ee p\u0159e\u017eit\u00ed onkologick\u00fdch pacient\u016f v Evrop\u011b stouplo. Hor\u0161\u00ed zpr\u00e1va je, \u017ee mezi regiony st\u00e1le z\u016fst\u00e1vaj\u00ed rozd\u00edly.<\/p>\n

P\u011btilet\u00e9 p\u0159e\u017eit\u00ed se v pr\u016fm\u011bru Evropy pohybuje od zhruba 80 procent u rakoviny prostaty \u010di prsu a\u017e po m\u00e9n\u011b ne\u017e 15 procent u rakoviny plic \u010di slinivky. Nejv\u00edc v Evrop\u011b stouplo p\u011btilet\u00e9 p\u0159e\u017eit\u00ed u rakoviny prostaty, ze 73 na 82 procent, a kone\u010dn\u00edku, z 52 na 58 procent.<\/p>\n

V \u010cesku dos\u00e1hlo p\u011btilet\u00e9 p\u0159e\u017eit\u00ed rakoviny prsu 78 procent, pr\u016fm\u011br Evropy je 81,8 procenta, pr\u016fm\u011br v\u00fdchodn\u00ed Evropy 73,7 procenta. Zlep\u0161en\u00ed v\u00fdsledk\u016f p\u0159inesl plo\u0161n\u00fd screening, zdravotn\u00ed poji\u0161\u0165ovny hrad\u00ed mamograf \u017een\u00e1m od 45 let jednou za dva roky, u mlad\u0161\u00edch \u017een je vy\u0161et\u0159en\u00ed prsou sou\u010d\u00e1st\u00ed pravideln\u00e9 preventivn\u00ed prohl\u00eddky u gynekologa \u010di praktika. Podobn\u011b u mu\u017e\u016f se l\u00e9ka\u0159i zam\u011b\u0159uj\u00ed na prevenci rakoviny prostaty. P\u011btilet\u00e9 p\u0159e\u017eit\u00ed tak v \u010cR \u010din\u00ed 78,2 procenta, pr\u016fm\u011br Evropy je 83,4 procenta, pr\u016fm\u011br v\u00fdchodn\u00ed Evropy 72 procenta.<\/p>\n

Od ledna za\u010dnou zdravotn\u00ed poji\u0161\u0165ovny v \u010cR rozes\u00edlat pozv\u00e1nky na prevenci – na screening n\u00e1dor\u016f prsu je dostane 494.651 \u017een, na screening rakoviny d\u011blo\u017en\u00edho hrdla 585.385 \u017een a na screening rakoviny tlust\u00e9ho st\u0159eva a kone\u010dn\u00edku 1,444.153 mu\u017e\u016f a \u017een. Projekt m\u00e1 pos\u00edlit dosavadn\u00ed prevenci – nyn\u00ed je ro\u010dn\u011b ve screeningu n\u00e1dor\u016f prsu p\u0159es 600.000 \u017een, n\u00e1dor\u016f d\u011blo\u017en\u00edho hrdla p\u0159es dva miliony \u017een a n\u00e1dor\u016f tlust\u00e9ho st\u0159eva a kone\u010dn\u00edku p\u016fl milionu mu\u017e\u016f a \u017een.<\/p>\n

P\u0159e\u017eit\u00ed je podle studie m\u011b\u0159\u00edtkem efektivity zdravotnick\u00e9ho syst\u00e9mu. V\u00fdsledky l\u00e9\u010dby zlep\u0161uje vyu\u017eit\u00ed \u00fa\u010dinn\u00fdch l\u00e9k\u016f a lep\u0161\u00ed opera\u010dn\u00ed techniky, plo\u0161n\u00fd screening a v\u010dasn\u00e1 diagnostika. Zhor\u0161uje je zat\u00ed\u017een\u00ed populace zhoubn\u00fdmi n\u00e1dory a \u017eivotn\u00ed styl v dan\u00e9 zemi. Nap\u0159\u00edklad rakovina \u017ealudku na jihu Evropy je m\u00e9n\u011b agresivn\u00ed ne\u017e v seversk\u00fdch zem\u00edch. \u010cesk\u00e1 populace je geneticky nejv\u00edce zat\u00ed\u017eena rakovinou tlust\u00e9ho st\u0159eva a kone\u010dn\u00edku.<\/p>\n

Italsk\u00fd t\u00fdm ocenil zem\u011b, kter\u00e9 maj\u00ed n\u00e1rodn\u00ed onkologick\u00fd program a v l\u00e9\u010db\u011b se \u0159\u00edd\u00ed mezin\u00e1rodn\u011b doporu\u010den\u00fdmi postupy. Oboje se t\u00fdk\u00e1 \u010cR. „\u010cR sv\u00fdmi nejnov\u011bj\u0161\u00edmi v\u00fdsledky upoutala evropskou ve\u0159ejnost a n\u00e1\u0161 informa\u010dn\u00ed syst\u00e9m pro hodnocen\u00ed onkologick\u00fdch center byl dokonce vybr\u00e1n jako model pro pilotn\u00ed zapracov\u00e1n\u00ed nov\u00fdch pravidel hodnocen\u00ed v EU,“ shrnul Du\u0161ek.<\/p>\n

 <\/p>\n

P\u011btilet\u00e9 p\u0159e\u017eit\u00ed rakoviny \u010cR, zem\u011b v\u00fdchodn\u00ed Evropy, pr\u016fm\u011br Evropy v procentech<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
rakovina<\/td>\n\u010cR<\/td>\nv\u00fdchodn\u00ed Evropa<\/td>\npr\u016fm\u011br Evropy<\/td>\n<\/tr>\n
prsu<\/td>\n78<\/td>\n73,7<\/td>\n81,8<\/td>\n<\/tr>\n
prostaty<\/td>\n78,2<\/td>\n72<\/td>\n83,4<\/td>\n<\/tr>\n
st\u0159eva<\/td>\n52,5<\/td>\n49,4<\/td>\n57<\/td>\n<\/tr>\n
\u017ealudku<\/td>\n22<\/td>\n18,8<\/td>\n25,1<\/td>\n<\/tr>\n
kone\u010dn\u00edku<\/td>\n48,7<\/td>\n44,6<\/td>\n55,8<\/td>\n<\/tr>\n
plic<\/td>\n11,5<\/td>\n10,6<\/td>\n13<\/td>\n<\/tr>\n
melanom<\/td>\n83,4<\/td>\n74,3<\/td>\n83,2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Zdroj: Eurocare
\nZhoubn\u00e9 novotvary – \u010cR 2000, 2010 a o\u010dek\u00e1van\u00e9 po\u010dty 2014<\/strong><\/p>\n\n\n\n\n\n\n\n
zhoubn\u00e9 n\u00e1dory<\/td>\n2000-nov\u00e1 onemocn\u011bn\u00ed<\/td>\n2000-\u00famrt\u00ed<\/td>\n2010-nov\u00e1 onemocn\u011bn\u00ed<\/td>\n2010-\u00famrt\u00ed<\/td>\n2014-o\u010dek\u00e1van\u00e9 po\u010dty nov\u00fdch onemocn\u011bn\u00ed<\/td>\n<\/tr>\n
n\u00e1dory celkem<\/td>\n58.410<\/td>\n28.539<\/td>\n77.035<\/td>\n27.834<\/td>\n<\/td>\n<\/tr>\n
hrdla d\u011blo\u017en\u00edho<\/td>\n1052<\/td>\n363<\/td>\n994<\/td>\n342<\/td>\n1022<\/td>\n<\/tr>\n
prsu<\/td>\n5004<\/td>\n1939<\/td>\n6498<\/td>\n1655<\/td>\n7313<\/td>\n<\/tr>\n
tlust\u00e9ho st\u0159eva a kone\u010dn\u00edku<\/td>\n7484<\/td>\n4336<\/td>\n8136<\/td>\n3810<\/td>\n8743<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Zdroj: Institut biostatiky a anal\u00fdz Masarykovy univerzity<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

P\u0159e\u017eit\u00ed pacient\u016f s rakovinou v \u010cR se podle studie Eurocare5 v\u00fdrazn\u011b prodlou\u017eilo, v\u00fdjimkou je rakovina kone\u010dn\u00edku, kde je kv\u016fli mal\u00e9mu z\u00e1jmu lid\u00ed o screening pozdn\u00ed […]<\/a><\/p>\n<\/div>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-13972","post","type-post","status-publish","format-standard","hentry","category-zdravi"],"_links":{"self":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts\/13972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13972"}],"version-history":[{"count":0,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts\/13972\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}